Sign In
Buy FBRX
$76.98
+0.450 (+0.588%)
At Close: Jul 30, 2026
Forte Biosciences, Inc. Announces Results and Provides Update
04:01pm, Thursday, 14'th Aug 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences Announces Pricing of $75 Million Public Offering
12:28am, Wednesday, 25'th Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a publ
Forte Biosciences Announces Proposed Public Offering
04:01pm, Tuesday, 24'th Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced
Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
07:18am, Monday, 23'rd Jun 2025
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
01:05pm, Thursday, 03'rd Apr 2025
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
10:01am, Friday, 03'rd Jan 2025
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
09:51am, Thursday, 28'th Nov 2024
Forte Biosciences (FBRX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thro
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 19'th Nov 2024
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
04:05pm, Friday, 17'th May 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
04:05pm, Monday, 13'th May 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
What Makes Forte Biosciences (FBRX) a New Buy Stock
01:01pm, Monday, 25'th Mar 2024
Forte Biosciences (FBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
04:05pm, Monday, 18'th Mar 2024
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
04:01pm, Friday, 01'st Dec 2023
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement aw
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting
10:50am, Thursday, 14'th Sep 2023
NEW YORK--(BUSINESS WIRE)--Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,”
